Effect of Edaravone in prevention of contrast-induced acute kidney injury (CI-AKI)
Phase 3
Recruiting
- Conditions
- Contrast induced nephropathy acute kidney injury (CIN-AKI).Other injury of kidneyS37.09
- Registration Number
- IRCT20201108049311N5
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Candidates for coronary angiography
Patients with kidney injury stage 4 and Stage 3B with GFR between 15 and 45
Patients with underlying diseases such as diabetes and lupus that cause renal failure
Exclusion Criteria
Pregnancy
lactation
Age over than 75 years
5-fold increased liver enzymes
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum creatinine level. Timepoint: Day 5 of contrast injection. Method of measurement: Biochemical methods.;Hospitalization duration. Timepoint: Number of hospitalization days after angiography. Method of measurement: Patients' documents.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Edaravone utilize to prevent contrast-induced acute kidney injury (CI-AKI)?
How does Edaravone compare to standard-of-care treatments for CI-AKI in clinical trials?
Are there specific biomarkers that identify patients most likely to benefit from Edaravone for CI-AKI prevention?
What are the potential adverse events associated with Edaravone in acute kidney injury prevention and how are they managed?
What other compounds or combination therapies are being explored for preventing contrast-induced nephropathy alongside Edaravone?